Matching articles for "Dificid"
Live Fecal Microbiota Oral Capsules (Vowst) for Prevention of CDI Recurrence
The Medical Letter on Drugs and Therapeutics • May 29, 2023; (Issue 1677)
The FDA has approved Vowst (Seres Therapeutics/Nestle HealthScience), an oral capsule containing live
fecal microbiota spores, for prevention of additional
recurrences of Clostridioides difficile infection...
The FDA has approved Vowst (Seres Therapeutics/Nestle HealthScience), an oral capsule containing live
fecal microbiota spores, for prevention of additional
recurrences of Clostridioides difficile infection (CDI)
in adults. Vowst is the first orally administered
microbiota-based treatment to be approved for
this indication. A rectally-administered live fecal
microbiota-based suspension (Rebyota) was
approved in 2022 for the same indication. Neither
product is approved for acute treatment of CDI.
Treatment of Clostridioides difficile Infection
The Medical Letter on Drugs and Therapeutics • September 6, 2021; (Issue 1632)
Clostridioides (formerly Clostridium) difficile infection
(CDI) is the most common infectious cause of
healthcare-associated diarrhea in adults. Guidelines
on management of CDI have recently been...
Clostridioides (formerly Clostridium) difficile infection
(CDI) is the most common infectious cause of
healthcare-associated diarrhea in adults. Guidelines
on management of CDI have recently been updated.
Firvanq - Vancomycin Oral Solution
The Medical Letter on Drugs and Therapeutics • July 16, 2018; (Issue 1551)
The FDA has approved vancomycin oral solution
(Firvanq – Cutis Pharma) for treatment of Clostridium
difficile-associated diarrhea and enterocolitis caused
by Staphylococcus aureus, including...
The FDA has approved vancomycin oral solution
(Firvanq – Cutis Pharma) for treatment of Clostridium
difficile-associated diarrhea and enterocolitis caused
by Staphylococcus aureus, including methicillin-resistant
strains (MRSA).
Bezlotoxumab (Zinplava) for Prevention of Recurrent Clostridium difficile Infection
The Medical Letter on Drugs and Therapeutics • March 27, 2017; (Issue 1517)
The FDA has approved the fully human monoclonal
antibody bezlotoxumab (Zinplava – Merck) for use
with antibacterial drug treatment to reduce recurrence
of Clostridium difficile infection (CDI) in adults...
The FDA has approved the fully human monoclonal
antibody bezlotoxumab (Zinplava – Merck) for use
with antibacterial drug treatment to reduce recurrence
of Clostridium difficile infection (CDI) in adults with
CDI at high risk for recurrence. It is the first drug to be
approved for this indication.
Drugs for Bacterial Infections
The Medical Letter on Drugs and Therapeutics • July 1, 2013; (Issue 131)
The text that follows reviews some common bacterial
infections and their empiric treatment pending the
results of culture and susceptibility testing. The recommendations
made here are based on the results...
The text that follows reviews some common bacterial
infections and their empiric treatment pending the
results of culture and susceptibility testing. The recommendations
made here are based on the results of
susceptibility studies, clinical trials, and the opinions
of Medical Letter reviewers. Tables 1 and 2 list the usual
dosages of antibacterial drugs.
Fidaxomicin (Dificid) for Clostridium Difficile Infection
The Medical Letter on Drugs and Therapeutics • September 19, 2011; (Issue 1373)
The FDA has approved fidaxomicin (Dificid – Optimer),
a new oral macrolide antibiotic, for treatment of
Clostridium difficile-associated diarrhea in patients
≥18 years old. The incidence and severity of...
The FDA has approved fidaxomicin (Dificid – Optimer),
a new oral macrolide antibiotic, for treatment of
Clostridium difficile-associated diarrhea in patients
≥18 years old. The incidence and severity of C. difficile
infection (CDI) have increased in recent years with the
emergence of an epidemic hypervirulent strain
(NAP1/B1/027), possibly related to widespread use of
fluoroquinolones.